These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10096531)
41. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559 [TBL] [Abstract][Full Text] [Related]
42. Lessons from cyclosporine monotherapy in renal transplantation: the impact of acute rejection on long-term allograft outcome. Coll E; Crespo M; Solé M; Campistol JM; Cofàn F; Esforzado N; Ricart MJ; Torregrosa JV; Oppenheimer F Transplant Proc; 2004 Mar; 36(2 Suppl):114S-116S. PubMed ID: 15041318 [TBL] [Abstract][Full Text] [Related]
43. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662 [TBL] [Abstract][Full Text] [Related]
44. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months. Aichberger C; Eberl T; Riedmann B; Pernthaler H; Ofner D; Königsrainer A; Margreiter R Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521 [TBL] [Abstract][Full Text] [Related]
45. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Nashan B; Light S; Hardie IR; Lin A; Johnson JR Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806 [TBL] [Abstract][Full Text] [Related]
46. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft. Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567 [TBL] [Abstract][Full Text] [Related]
48. A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management. Dean DE; Kamath S; Peddi VR; Schroeder TJ; First MR; Cavallo T Transplantation; 1999 Sep; 68(5):642-5. PubMed ID: 10507482 [TBL] [Abstract][Full Text] [Related]
49. Effect of early cyclosporine levels on kidney allograft rejection. Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683 [TBL] [Abstract][Full Text] [Related]
50. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
51. An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome. Bates WD; Davies DR; Welsh K; Gray DW; Fuggle SV; Morris PJ Nephrol Dial Transplant; 1999 Oct; 14(10):2364-9. PubMed ID: 10528659 [TBL] [Abstract][Full Text] [Related]
52. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835 [TBL] [Abstract][Full Text] [Related]